Background: Isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate to 2-oxoglutarate. Mutations of Arg-132 in IDH to Cys, His, Leu or Ser abolish magnesium binding and the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R-2-hydroxyglutarate. Elevated levels of R-2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors.
Immunogen: A synthetic peptide from the internal region of IDH2 which includes the mutation of R140Q, human origin.
Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 50% glycerol
Species Reactivity: Recognizes R140Q mutant, but not wild-type IDH2 of vertebrates.
Storage Conditions: Store at -20°C. Avoid freeze / thaw cycles
Western blot:
Western blot analysis of recombinant IDH2 (R140Q) and wildtype proteins. Purified His-tagged IDH2 (R140Q) protein (lane 2) and corresponding wildtype protein (lane 1) were blotted with anti-IDH2 (R140Q) monoclonal antibody (Cat. #26165).
Immunofluorescence:
Immunofluorescence of cells expressing IDH2 proteins with anti-IDH2 (R140Q) antibody. HEK293T cells were transfected with pCDNA3-GFP-IDH2 (WT) plasmid (left column) or pCDNA3-GFP-IDH2 (R140Q) plasmid (right column), then fixed and stained with anti-IDH2 (R140Q) monoclonal antibody (Cat. #26165).
![α-萘乙酸[NAA]【科研、组培用】](http://www.cnbio.net/file/upload/202409/04/17171473211147.jpg.middle.jpg)
![6-苄氨基嘌呤[6-BA]【科研、组织培养用】](http://www.cnbio.net/file/upload/202409/04/17140735211147.jpg.middle.jpg)